Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel ONWARD MEDICAL BRU:ONWD.BL, NL0015000HT4

  • 5,180 21 mei 2024 17:35
  • +0,260 (+5,28%) Dagrange 5,160 - 5,480
  • 228.314 Gem. (3M) 100,2K

Forum Onward Medical geopend

1.283 Posts
Pagina: «« 1 ... 60 61 62 63 64 65 »» | Laatste | Omlaag ↓
  1. forum rang 7 Kaviaar 10 april 2024 12:51
    Stifel Initiates Research Coverage of ONWARD® Medical with
    a Buy Rating and Target Price of EUR 12.00


    EINDHOVEN, the Netherlands — April 9, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
    the medical technology company creating innovative therapies to restore movement, function,
    and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-
    based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy
    rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price
    of EUR 5.00 on April 8, 2024.

    The initiation report was published April 8, 2024. Stifel joins four other banks whose analysts
    cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial
    premiums to the current share price.
    “Stifel’s initiation of coverage reflects the value they place on the strategic positioning of our
    brain-computer interface (BCI) platform as well as their strong confidence in our ability to
    achieve this year’s milestones, which include the planned commercialization of our ARC-EX®
    platform later this year,” said Dave Marver, CEO of ONWARD Medical. “Stifel is the largest
    provider of global small-cap equity research, and we are gratified they recognize the value
    ONWARD can create for investors in coming quarters.”
    To learn more about ONWARD Medical’s commitment to partnering with the SCI community to
    develop innovative solutions for restoring movement, function, and independence after spinal
    cord injury, please visit ONWD.com.

    *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-
    BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are
    investigational and not available for commercial use.
  2. forum rang 5 Stork 49 10 april 2024 16:08
    quote:

    Kaviaar schreef op 10 april 2024 12:51:

    Stifel Initiates Research Coverage of ONWARD® Medical with
    a Buy Rating and Target Price of EUR 12.00


    EINDHOVEN, the Netherlands — April 9, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
    the medical technology company creating innovative therapies to restore movement, function,
    and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-
    based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy
    rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price
    of EUR 5.00 on April 8, 2024.

    The initiation report was published April 8, 2024. Stifel joins four other banks whose analysts
    cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial
    premiums to the current share price.
    “Stifel’s initiation of coverage reflects the value they place on the strategic positioning of our
    brain-computer interface (BCI) platform as well as their strong confidence in our ability to
    achieve this year’s milestones, which include the planned commercialization of our ARC-EX®
    platform later this year,” said Dave Marver, CEO of ONWARD Medical. “Stifel is the largest
    provider of global small-cap equity research, and we are gratified they recognize the value
    ONWARD can create for investors in coming quarters.”
    To learn more about ONWARD Medical’s commitment to partnering with the SCI community to
    develop innovative solutions for restoring movement, function, and independence after spinal
    cord injury, please visit ONWD.com.

    *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-
    BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are
    investigational and not available for commercial use.
    heel interessant maar we wisten het al; je hebt kennelijk iets gemist gisteren
  3. forum rang 7 Kaviaar 11 april 2024 18:49
    ONWARD® Medical Announces Publication of Full Year 2023
    Financial Results and Business Update Webcast

    EINDHOVEN, the Netherlands — April 11, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
    the medical technology company creating innovative spinal cord stimulation therapies to restore
    movement, function, and independence in people with spinal cord injury (SCI), today announces
    that it will publish Full Year 2023 Financial Results and host a webcast to discuss business
    highlights.
    The webcast will be held on April 25, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by
    CEO Dave Marver and Interim CFO Khaled Bahi, who will discuss highlights from 2023 and
    provide a business update.

    ir.onwd.com/static-files/f5e9e0d4-54a...
  4. forum rang 5 Stork 49 16 april 2024 09:14
    quote:

    Blik dekkende afbijt schreef op 16 april 2024 09:10:

    Wanneer komen ze met je jaarcijfers?
    Ik dacht deze week.
    Die website van deze tent is de slechte die ik ooit in mijn leven ben tegengekomen.
    en jij bent d slechtste lezer als het gaat om bijdragen van anderen; daar vind je het het antwoord
  5. biobert 16 april 2024 12:43
    quote:

    Dagobert Duck schreef op 16 april 2024 12:40:

    Onward behoort helaas wel weer bij de top drie van grootste dalers op de beurs vandaag!
    En dat zonder enige reden.
    Reden: de winst van Onward ligt verder in de toekomst en moet worden teruggerekend met de huidige stijgende rente. Het gevolg is dat de waarde van het aandeel daalt.
  6. forum rang 7 Kaviaar 16 april 2024 17:23
    quote:

    Dagobert Duck schreef op 16 april 2024 12:40:

    Onward behoort helaas wel weer bij de top drie van grootste dalers op de beurs vandaag!
    En dat zonder enige reden.
    Misschien kapers op de kust?
    Ik verwacht dat Onward t.z.t. van de FDA goedkeuring krijgt.
    Dan is er enorme potentie voor de producten van Onward.
    Als je de koers laag kan houden, dan kan je het bedrijf relatief goedkoop overnemen.
    Ik denk meer in die richting.
  7. VBR 17 april 2024 09:05
    quote:

    Kaviaar schreef op 16 april 2024 17:38:

    Krijgen we nog te zien welke grootaandeelhouders meegedaan hebben met de emissie?
    Of hebben ze ervoor gezorgd dat het aantal gelijk gebleven is, door al bestaande aandelen te verkopen zodat hun belang gelijk blijft?
    ir.onwd.com/static-files/6715816c-f96...

    "Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333
    shares respectively allocated to INKEF Capital and EQT Life Sciences. Following the Offerings,
    INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s
    share capital. An aggregate of 246,555 shares were also allocated to the following
    management, founders, and members of the Board of Directors of the Company: Dave Marver,
    CEO; Robert Odell, VP Operations; Lorenzo Fanti, VP Legal; Co-Founders Jocelyne Bloch and
    Grégoire Courtine, CSO; and Directors Ian Curtis, Kristina Dziekan, and Fred Colen."
  8. h980577. 17 april 2024 19:24
    quote:

    VBR schreef op 17 april 2024 09:05:

    [...]

    ir.onwd.com/static-files/6715816c-f96...

    "Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333
    shares respectively allocated to INKEF Capital and EQT Life Sciences. Following the Offerings,
    INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s
    share capital. An aggregate of 246,555 shares were also allocated to the following
    management, founders, and members of the Board of Directors of the Company: Dave Marver,
    CEO; Robert Odell, VP Operations; Lorenzo Fanti, VP Legal; Co-Founders Jocelyne Bloch and
    Grégoire Courtine, CSO; and Directors Ian Curtis, Kristina Dziekan, and Fred Colen."
    Op de site van Gimv zie ik niets over deze kapitaalronde. Zullen dus waarschijnlijk ook niet hebben meegedaan, bovenstaande ook lezende waar Gimv ook niet wordt genoemd.
  9. Renno54 19 april 2024 23:16
    Onderstaand stukje gekopieerd uit LinkedIn. Van ongeveer een week geleden. Had dit op het forum nog niet gezien.

    Today is World Parkinson’s Day, which is an opportunity to raise awareness about Parkinson’s disease (PD), a complex, progressive disease that affects the nervous system. We honor those who struggle with the disease and their caregivers. We also salute those working to advance research to find a cure for Parkinson’s disease.

    We are grateful for our partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF) in furthering our work in this field and learning more about how our therapies might address some of the symptoms related to PD. Because PD can cause tremor, slowness, stiffness, and walking and balance problems, it is called a “movement disorder,” according to MJFF.

    Last fall, we announced the publication of a Nature Medicine article highlighting the use of our investigational ARC Therapy™ to address gait challenges related to Parkinson’s disease. The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades. He has a severe gait disorder that has not responded to conventional therapies. After the introduction of ARC Therapy and benefitting from a few weeks of rehabilitation, the study participant was able to walk without previously noticeable gait interruptions.

    Our research partner .NeuroRestore was awarded a $1 million grant from MJFF to study the effect of our ARC Therapy in six additional participants with Parkinson’s disease. We look forward to continuing to learn about the potential for the same technology platform and therapy we are developing for spinal cord injury to also address mobility challenges stemming from Parkinson’s disease.
    On this day of awareness, we appreciate the chance to collaborate with those in the field to work towards innovative solutions.

    *All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
  10. forum rang 7 Kaviaar 20 april 2024 08:37
    Bedankt Renno54. Wereldwijd zijn er 10 miljoen mensen die de ziekte Parkinson hebben. Als Onward een deel kan helpen met hun producten, dan zou dat voor deze mensen geweldig zijn. En dat door een NL bedrijf.

    www.parkinsonnet.nl/parkinson/#:~:tex...,is%20voor%20geen%20mens%20hetzelfde.
1.283 Posts
Pagina: «« 1 ... 60 61 62 63 64 65 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links